EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

doi:10.1007/s00259-018-3947-x

. 2018 May;45(5):846-859.

doi: 10.1007/s00259-018-3947-x. Epub 2018 Feb 16.

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

Daria Handkiewicz-Junak¹, Thorsten D Poeppel², Lisa Bodei³, Cumali Aktolun⁴, Samer Ezziddin⁵, Francesco Giammarile⁶, Roberto C Delgado-Bolton⁷, Michael Gabriel^{8

9}

Affiliations

¹ Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. Daria.Handkiewicz-Junak@io.gliwice.pl.
² Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany.
³ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
⁴ Tirocenter Nuclear Medicine Center, Istanbul, Turkey.
⁵ Nuclear Medicine, University Hospital USK, Saarland University, Hamburg, Germany.
⁶ Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency (IAEA), Vienna, Austria.
⁷ Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain. rbiolton@gmail.com.
⁸ Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria.
⁹ University Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

PMID: 29453701
PMCID: PMC5978928
DOI: 10.1007/s00259-018-3947-x

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

Daria Handkiewicz-Junak et al. Eur J Nucl Med Mol Imaging. 2018 May.

. 2018 May;45(5):846-859.

doi: 10.1007/s00259-018-3947-x. Epub 2018 Feb 16.

Authors

Daria Handkiewicz-Junak¹, Thorsten D Poeppel², Lisa Bodei³, Cumali Aktolun⁴, Samer Ezziddin⁵, Francesco Giammarile⁶, Roberto C Delgado-Bolton⁷, Michael Gabriel^{8

9}

Affiliations

¹ Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. Daria.Handkiewicz-Junak@io.gliwice.pl.
² Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany.
³ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
⁴ Tirocenter Nuclear Medicine Center, Istanbul, Turkey.
⁵ Nuclear Medicine, University Hospital USK, Saarland University, Hamburg, Germany.
⁶ Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency (IAEA), Vienna, Austria.
⁷ Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain. rbiolton@gmail.com.
⁸ Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria.
⁹ University Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

PMID: 29453701
PMCID: PMC5978928
DOI: 10.1007/s00259-018-3947-x

Abstract

The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (⁸⁹Sr), samarium-153 (¹⁵³Sm) lexidronam (¹⁵³Sm-EDTMP), and phosphorus-32 (³²P) sodium phosphate; (b) performing the treatments; and

Keywords: Beta-emitting radionuclides; Bone metastases; Efficacy; Phosphorus-32; Radionuclide therapy; Samarium-153; Strontium-89.

©) understanding and evaluating the treatment outcome and side effects.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

D.H.-J declares travel grants and lecture fees from Sanofi-Genzyme, Novartis and Ipsen.

L.B. declares consultancy for Advanced Accelerator Applications and Ipsen.

T.D.P., C.A., S.E., F.G., R.C.D.-B. and M.G. declare no conflicts of interest.

Research involving human participants and/or animals

This article does not describe any studies with human participants or animals performed by any of the authors. This is not a research article.

Informed consent

No informed consent was needed.

Cited by

Superscan Pattern on Bone Scintigraphy: A Comprehensive Review.
Askari E, Shakeri S, Roustaei H, Fotouhi M, Sadeghi R, Harsini S, Vali R. Askari E, et al. Diagnostics (Basel). 2024 Oct 6;14(19):2229. doi: 10.3390/diagnostics14192229. Diagnostics (Basel). 2024. PMID: 39410633 Free PMC article. Review.
Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.
Andrew J, Ezra-Manicum AL, Witika BA. Andrew J, et al. EJNMMI Radiopharm Chem. 2024 Aug 24;9(1):62. doi: 10.1186/s41181-024-00295-7. EJNMMI Radiopharm Chem. 2024. PMID: 39180599 Free PMC article. Review.
Localized radiotherapy of solid tumors using radiopharmaceutical loaded implantable system: insights from a mathematical model.
Piranfar A, Souri M, Rahmim A, Soltani M. Piranfar A, et al. Front Oncol. 2024 Feb 26;14:1320371. doi: 10.3389/fonc.2024.1320371. eCollection 2024. Front Oncol. 2024. PMID: 38559559 Free PMC article.
Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.
Winuprasith T, Koirala P, McClements DJ, Khomein P. Winuprasith T, et al. Int J Nanomedicine. 2023 Aug 3;18:4449-4470. doi: 10.2147/IJN.S416737. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37555189 Free PMC article. Review.
Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.
Altena R, Tzortzakakis A, Af Burén S, Tran TA, Frejd FY, Bergh J, Axelsson R. Altena R, et al. EJNMMI Res. 2023 May 17;13(1):43. doi: 10.1186/s13550-023-00995-2. EJNMMI Res. 2023. PMID: 37195374 Free PMC article. Review.

See all "Cited by" articles

References

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66. doi: 10.1038/bjc.1987.13. - DOI - PMC - PubMed
1. Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335:1124–1132. doi: 10.1056/NEJM199610103351507. - DOI - PubMed
1. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18. doi: 10.1016/S0304-3959(96)03267-8. - DOI - PubMed
1. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509–524. doi: 10.1200/JCO.1991.9.3.509. - DOI - PubMed
1. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi: 10.1056/NEJMoa1213755. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66. doi: 10.1038/bjc.1987.13. - DOI - PMC - PubMed

[2] Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66. doi: 10.1038/bjc.1987.13. - DOI - PMC - PubMed

[3] Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335:1124–1132. doi: 10.1056/NEJM199610103351507. - DOI - PubMed

[4] Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med. 1996;335:1124–1132. doi: 10.1056/NEJM199610103351507. - DOI - PubMed

[5] Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18. doi: 10.1016/S0304-3959(96)03267-8. - DOI - PubMed

[6] Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18. doi: 10.1016/S0304-3959(96)03267-8. - DOI - PubMed

[7] Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509–524. doi: 10.1200/JCO.1991.9.3.509. - DOI - PubMed

[8] Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509–524. doi: 10.1200/JCO.1991.9.3.509. - DOI - PubMed

[9] Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi: 10.1056/NEJMoa1213755. - DOI - PubMed

[10] Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223. doi: 10.1056/NEJMoa1213755. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

Affiliations

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides

Authors

Affiliations

Abstract

Conflict of interest statement

Conflicts of interest

Research involving human participants and/or animals

Informed consent

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Abstract

Conflict of interest statement

Conflicts of interest

Research involving human participants and/or animals

Informed consent

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials